We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Should Move on Follow-On Biologics, Hatch, Waxman Say
FDA Should Move on Follow-On Biologics, Hatch, Waxman Say
September 23, 2005
The FDA’s current policy on follow-on biologics amounts to a “monopoly” situation for brand firms, according to two prominent lawmakers who helped shape the current generic drug industry.